Health and Fitness Health and Fitness
Mon, November 1, 2010
[ Mon, Nov 01st 2010 ] - Market Wire
Oncolytics Biotech(R) Inc. Collaborators to Prese .. t Reovirus Research at the EORTC-NCI-AACR Meeting
[ Mon, Nov 01st 2010 ] - Market Wire
NeoStem to Present at Cell Therapy Industry Summi .. eld on November 3-5, 2010 in Carlsbad, California
[ Mon, Nov 01st 2010 ] - Market Wire
Clinical Data, Inc. Granted Orphan Drug Designati .. for PRX-8066 for Pulmonary Arterial Hypertension
[ Mon, Nov 01st 2010 ] - Market Wire
Gileada?s onderzoeksverbindingen GS 9190 en GS 92 .. erking met standaard zorgtherapien bereiken subst
[ Mon, Nov 01st 2010 ] - Market Wire
Inhibitex Initiates Phase 1b Multiple Ascending D .. l of INX-189 in Patients with Chronic Hepatitis C
[ Mon, Nov 01st 2010 ] - Market Wire
American Anesthesiology Announces the Acquisition of Greensboro, NC, Group Practice
[ Mon, Nov 01st 2010 ] - Market Wire
Hepatitis-C-Prfprparate GS 9190 und GS 9256 von G .. Phase II zusammen mit Standardtherapien wesentli
[ Mon, Nov 01st 2010 ] - Market Wire
ARIAD to Webcast Conference Call on Third Quarter 2010 Financial Results
[ Mon, Nov 01st 2010 ] - Market Wire
Orthovita to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Theragenics to Report Third Quarter 2010 Financial Results Tuesday, November 9
[ Mon, Nov 01st 2010 ] - Market Wire
I composti sperimentali per l'epatite C di Gilead .. azione con terapie standard di cura ottengono una
[ Mon, Nov 01st 2010 ] - Market Wire
Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention
[ Mon, Nov 01st 2010 ] - Market Wire
Health Management Associates, Inc. to Present at the Oppenheimer 21st Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Porex Corporation Divests Surgical Division to Stryker Corporation
[ Mon, Nov 01st 2010 ] - Market Wire
Medisafe 1 Technologies Appoints Tali Skoczylas as Chair of Medical Advisory Board
Sat, October 30, 2010
[ Sat, Oct 30th 2010 ] - Market Wire
A Celgene anuncia resultados financeiros e operacionais recordes no terceiro trimestre de 2010
[ Sat, Oct 30th 2010 ] - Market Wire
Viread® for Hepatitis B Maintains Antiviral Supp .. ent of Resistance Through Four Years of Treatment
[ Sat, Oct 30th 2010 ] - Market Wire
New Data From Phase 3 Studies Showed Superior SVR .. with Telaprevir-Based Combination Therapy in Peop
[ Sat, Oct 30th 2010 ] - Market Wire
Salix Pharmaceuticals Previews Data Slated for Pr .. ting of the American Association for the Study of
[ Sat, Oct 30th 2010 ] - Market Wire
Gileada?s Investigational Hepatitis C Compounds G .. tion with Standard of Care Therapies Achieve Subs
Fri, October 29, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Announces a Stron .. eement with Majority of Senior Subordinated Noteh
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
[ Fri, Oct 29th 2010 ] - Market Wire
Forest Announces FDA Approval of Teflaroa" (cefta .. ment of Community-Acquired Bacterial Pneumonia an
[ Fri, Oct 29th 2010 ] - Market Wire
FDA Classifies Previous Field Action of Medtronic Surgical Device as Class I Recall
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Present at Two Upcoming Investor Conferences
[ Fri, Oct 29th 2010 ] - Market Wire
ArthroCare Announces Third Quarter 2010 Financial Results Press Release and Conference Call Dates
[ Fri, Oct 29th 2010 ] - Market Wire
Wright Medical Group, Inc. to Participate in the 2010 Annual Credit Suisse Healthcare Conference
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 9, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Fitch Affirms Boston Scientific's IDR at 'BB+'; Outlook to Positive
[ Fri, Oct 29th 2010 ] - Market Wire
Ligand to Report Third Quarter Results on November 9

Ligand to Report Third Quarter Results on November 9


Published on 2010-10-29 10:11:45 - Market Wire
  Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report third quarter 2010 financial results on Tuesday, November 9, 2010. Liganda™s President and CEO, John L. Higgins and Vice President of Finance and CFO, John Sharp will host the conference call.

Third Quarter Earnings Call

What: Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.
When: Tuesday, November 9, 2010
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
Webcast:

Conference call and replay accessible at [ www.ligand.com ].

Conference Call: (877) 407-4019, passcode: Ligand
(201) 689-8337 outside the U.S.
Replay: (877) 660-6853, Account #: 361 passcode: 359601 (201) 612-7415 outside the U.S.

About Ligand Pharmaceuticals

Ligand discovers and develops novel drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, tissue-specific receptor ligand interactions and gene-expression tools. Among its peers, we believe Ligand has assembled one of the largest portfolio of assets including commercial therapies developed in partnership with pharmaceutical companies. Ligand has alliances with the world's leading pharmaceutical companies including GlaxoSmithKline (GSK), Merck, Pfizer, Roche, Bristol-Myers Squibb and AstraZeneca, and has more than 30 programs in various stages of development.

Contributing Sources